Immune checkpoint inhibitor use in head and neck squamous cell carcinoma: the current landscape and future perspectives

References

• Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229–263. doi:10.3322/caac.21834
   PubMed Web of Science ®Google Scholar
• Gormley M, Creaney G, Schache A, Ingarfield K, Conway DI. Reviewing the epidemiology of head and neck cancer: definitions, trends and risk factors. Br Dent J 2022;233(9):780–786.
   PubMed Web of Science ®Google Scholar
• Gillison ML, Chaturvedi AK, Anderson WF, Fakhry C. Epidemiology of human papillomavirus-positive head and neck squamous cell carcinoma. J Clin Oncol. 2015;33(29):3235–3242. doi:10.1200/JCO.2015.61.6995
   PubMed Web of Science ®Google Scholar
• Sadeghi Rad H, Monkman J, Warkiani ME, Ladwa R, O'Byrne K, Rezaei N, et al. Understanding the tumor microenvironment for effective immunotherapy. Med Res Rev. 2021;41(3):1474–1498. doi:10.1002/med.21765
   PubMed Web of Science ®Google Scholar
• Dummer RG, Mony JT, Otsuka A, Seidel JA, Kabashima K. Anti-PD-1 and anti-CTLA-4 therapies in cancer: mechanisms of action, efficacy, and limitations. Artic Oncol. 2018;86(1):86.
   Google Scholar
• Wherry EJ. T cell exhaustion. Nat Immunol. 2011;12(6):492–499. doi:10.1038/ni.2035
   PubMed Web of Science ®Google Scholar
• Jiang Y, Li Y, Zhu B. T-cell exhaustion in the tumor microenvironment. Cell Death Dis. 2015;6(6):e1792–e1792. doi:10.1038/cddis.2015.162
   PubMed Web of Science ®Google Scholar
• Nagasaki J, Ishino T, Togashi Y. Mechanisms of resistance to immune checkpoint inhibitors. Cancer Sci. 2022;113(10):3303–3312. doi:10.1111/cas.15497
   PubMed Web of Science ®Google Scholar
• Shiravand Y, Khodadadi F, Kashani SMA, Hosseini-Fard SR, Hosseini S, Sadeghirad H, et al. Immune checkpoint inhibitors in cancer therapy. Curr Oncol. 2022;29(5):3044–3060. doi:10.3390/curroncol29050247
   PubMed Web of Science ®Google Scholar
• Foster CC, Couey MA, Kochanny SE, Khattri A, Acharya RK, Tan Y-HC, et al. Immune-related adverse events are associated with improved response, progression-free survival, and overall survival for patients with head and neck cancer receiving immune checkpoint inhibitors. Cancer. 2021;127(24):4565–4573. doi:10.1002/cncr.33780
   PubMed Web of Science ®Google Scholar
• Damasio MPS, Nascimento CS, Andrade LM, de Oliveira VL, Calzavara-Silva CE. The role of T-cells in head and neck squamous cell carcinoma: from immunity to immunotherapy. Front Oncol. 2022;12:1021609. doi:10.3389/fonc.2022.1021609
   PubMedGoogle Scholar
• Kyzas PA, Cunha IW, Ioannidis JPA. Prognostic significance of vascular endothelial growth factor immunohistochemical expression in head and neck squamous cell carcinoma: a meta-analysis. Clin Cancer Res. 2005;11(4):1434–1440. doi:10.1158/1078-0432.CCR-04-1870
   PubMed Web of Science ®Google Scholar
• Mineta H, Miura K, Ogino T, Takebayashi S, Misawa K, Ueda Y, et al. Prognostic value of vascular endothelial growth factor (VEGF) in head and neck squamous cell carcinomas. Br J Cancer. 2000;83(6):775–781. doi:10.1054/bjoc.2000.1357
   PubMed Web of Science ®Google Scholar
• Byeon HK, Ku M, Yang J. Beyond EGFR inhibition: multilateral combat strategies to stop the progression of head and neck cancer. Exp Mol Med. 2019;51(1):1–14. doi:10.1038/s12276-018-0202-2
   PubMed Web of Science ®Google Scholar
• Ferris RL, Blumenschein G, Fayette J, Guigay J, Colevas A, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 2016;375:1856–1867. doi:10.1056/NEJMoa1602252
   PubMed Web of Science ®Google Scholar
• Cohen EEW, Soulières D, Le Tourneau C, Dinis J, Licitra L, Ahn M-J, et al. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, Phase III study. Lancet. 2019;393(10167):156–167. doi:10.1016/S0140-6736(18)31999-8
   PubMed Web of Science ®Google Scholar
• Burtness B, Harrington KJ, Greil R, Soulières D, Tahara M, de Castro G, et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, Phase III study. Lancet. 2019;394(10212):1915–1928. doi:10.1016/S0140-6736(19)32591-7
   PubMed Web of Science ®Google Scholar
• Rivera F, García-Castaño A, Vega N, Vega-Villegas ME, Gutiérrez-Sanz L. Cetuximab in metastatic or recurrent head and neck cancer: the EXTREME trial. Expert Rev Anticancer Ther. 2009;9(10):1421–1428. doi:10.1586/era.09.113
   PubMed Web of Science ®Google Scholar
• Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008;359(11):1116–1127. doi:10.1056/NEJMoa0802656
   PubMed Web of Science ®Google Scholar
• Guigay J, Fayette J, Mesia R, Lafond C, Saada-Bouzid E, Geoffrois L, et al. TPExtreme randomized trial: TPEx versus extreme regimen in 1st line recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). J Clin Oncol. 2019;37(Suppl. 15):6002. doi:10.1200/JCO.2019.37.15_suppl.6002
   Google Scholar
• Shitara K, Van Cutsem E, Bang Y-J, Fuchs C, Wyrwicz L, Lee K-W, et al. Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer: the KEYNOTE-062 phase randomized clinical trial. JAMA Oncol. 2020;6(10):1571–1580. doi:10.1001/jamaoncol.2020.3370
   PubMed Web of Science ®Google Scholar
• Mok TSK, Wu Y-L, Kudaba I, Kowalski DM, Cho BC, Turna HZ, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, Phase III trial. Lancet. 2019;393(10183):1819–1830. doi:10.1016/S0140-6736(18)32409-7
   PubMed Web of Science ®Google Scholar
• Burtness B, Rischin D, Greil R, Soulières D, Tahara M, de Castro G Jr, et al. Pembrolizumab alone or with chemotherapy for recurrent/metastatic head and neck squamous cell carcinoma in KEYNOTE-048: subgroup analysis by programmed death ligand-1 combined positive score. J Clin Oncol. 2022;40(21):2321–2332. doi:10.1200/JCO.21.02198
   PubMed Web of Science ®Google Scholar
• Wheeler DL, Huang S, Kruser TJ, Nechrebecki MM, Armstrong EA, Benavente S, et al. Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members. Oncogene. 2008;27(28):3944–3956. doi:10.1038/onc.2008.19
   PubMed Web of Science ®Google Scholar
• Borcoman E, Nandikolla A, Long G, Goel S, Le Tourneau C. Patterns of response and progression to immunotherapy. Am Soc Clin Oncol Educ B. 2018;38:169–178. doi:10.1200/EDBK_200643
   PubMedGoogle Scholar
• Bedmutha A, Kaushal A. Pseudoprogression during immunotherapy in metastatic head and neck squamous cell carcinoma. Radiol Imaging Cancer. 2022;4(3):e220037. doi:10.1148/rycan.220037
   PubMedGoogle Scholar
• Seymour L, Bogaerts J, Perrone A, Ford R, Schwartz LH, Mandrekar S, et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 2017;18(3):e143–e152. doi:10.1016/S1470-2045(17)30074-8
   PubMed Web of Science ®Google Scholar
• Saâda-Bouzid E, Defaucheux C, Karabajakian A, Coloma VP, Servois V, Paoletti X, et al. Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. Ann Oncol. 2017;28(7):1605–1611. doi:10.1093/annonc/mdx178
   PubMed Web of Science ®Google Scholar
• Champiat S, Dercle L, Ammari S, Massard C, Hollebecque A, Postel-Vinay S, et al. Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1. Clin Cancer Res. 2017;23(8):1920–1928. doi:10.1158/1078-0432.CCR-16-1741
   PubMed Web of Science ®Google Scholar
• Camelliti S, Le Noci V, Bianchi F, Moscheni C, Arnaboldi F, Gagliano N, et al. Mechanisms of hyperprogressive disease after immune checkpoint inhibitor therapy: what we (don't) know. J Exp Clin Cancer Res. 2020;39(1):236. doi:10.1186/s13046-020-01721-9
   PubMed Web of Science ®Google Scholar
• Forsyth S, Yip K, Foran B, Gougis P, Wheeler G, White L, et al. 979TiP POPPY: a Phase II trial to assess the efficacy and safety profile of pembrolizumab in patients with performance status 2 with recurrent or metastatic squamous cell carcinoma of the head and neck. Ann Oncol. 2020;31:S686–S687. doi:10.1016/j.annonc.2020.08.1094
   Google Scholar
• Ferris RL, Haddad R, Even C, Tahara M, Dvorkin M, Ciuleanu TE, et al. Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label Phase III study. Ann Oncol. 2020;31(7):942–950. doi:10.1016/j.annonc.2020.04.001
   PubMed Web of Science ®Google Scholar
• Psyrri A, Fayette J, Harrington K, Gillison M, Ahn M-J, Takahashi S, et al. Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a randomized, open-label, Phase III study. Ann Oncol. 2023;34(3):262–274. doi:10.1016/j.annonc.2022.12.008
   PubMed Web of Science ®Google Scholar
• Haddad RI, Harrington K, Tahara M, Ferris RL, Gillison M, Fayette J, et al. Nivolumab plus ipilimumab versus EXTREME regimen as first-line treatment for recurrent/metastatic squamous cell carcinoma of the head and neck: the final results of CheckMate 651. J Clin Oncol. 2023;41(12):2166–2180. doi:10.1200/JCO.22.00332
   PubMed Web of Science ®Google Scholar
• Harrington KJ, Ferris RL, Gillison M, Tahara M, Argiris A, Fayette J, et al. Efficacy and safety of nivolumab plus ipilimumab vs nivolumab alone for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck: the Phase II CheckMate 714 randomized clinical trial. JAMA Oncol. 2023;9(6):779–789. doi:10.1001/jamaoncol.2023.0147
   PubMed Web of Science ®Google Scholar
• Gavrielatou N, Doumas S, Economopoulou P, Foukas PG, Psyrri A. Biomarkers for immunotherapy response in head and neck cancer. Cancer Treat Rev. 2020;84(August 2019):101977. doi:10.1016/j.ctrv.2020.101977
   PubMedGoogle Scholar
• Deng L, Liang H, Burnette B, Beckett M, Darga T, Weichselbaum RR, et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Invest. 2014;124(2):687–695. doi:10.1172/JCI67313
   PubMed Web of Science ®Google Scholar
• Demaria S, Guha C, Schoenfeld J, Morris Z, Monjazeb A, Sikora A, et al. Radiation dose and fraction in immunotherapy: one-size regimen does not fit all settings, so how does one choose? J Immunother Cancer. 2021;9(4):e002038. doi:10.1136/jitc-2020-002038
   PubMed Web of Science ®Google Scholar
• Formenti SC, Demaria S. Combining radiotherapy and cancer immunotherapy: a paradigm shift. J Natl Cancer Inst. 2013;105(4):256–265. doi:10.1093/jnci/djs629
   PubMed Web of Science ®Google Scholar
• Morisada M, Clavijo PE, Moore E, Sun L, Chamberlin M, Van Waes C, et al. PD-1 blockade reverses adaptive immune resistance induced by high-dose hypofractionated but not low-dose daily fractionated radiation. Oncoimmunology. 2018;7(3):e1395996. doi:10.1080/2162402X.2017.1395996
   PubMed Web of Science ®Google Scholar
• Wang Y. Advances in hypofractionated irradiation-induced immunosuppression of tumor microenvironment. Front Immunol. 2020;11:612072.
   PubMed Web of Science ®Google Scholar
• Jacob A, Kreimer A, Wei J, Wu J, Corum L, Reusch E, et al. Priming immunotherapy with radiotherapy (RT) in advanced non-small cell lung cancer (NSCLC) and head and neck squamous cell cancer (HNSCC): interim analysis of Phase II clinical trial. J Clin Oncol. 2021;39(Suppl. 15):2628–2628. doi:10.1200/JCO.2021.39.15_suppl.2628
   Google Scholar
• Bahig H, Aubin F, Nguyen-Tan PF, Souliere D, Palma DA, Charpentier D, et al. Initial analyses of a Phase I/II trial of durvalumab (D) plus tremelimumab (T) and stereotactic body radiotherapy (SBRT) for oligometastatic head and neck carcinoma. J Clin Oncol. 2020;38(Suppl. 15):6531. doi:10.1200/JCO.2020.38.15_suppl.6531
   Web of Science ®Google Scholar
• Spaas M, Sundahl N, Kruse V, Rottey S, De Maeseneer D, Duprez F, et al. Checkpoint inhibitors in combination with stereotactic body radiotherapy in patients with advanced solid tumors: the CHEERS Phase II randomized clinical trial. JAMA Oncol. 2023;21(1):514.
   Google Scholar
• McBride S, Sherman E, Tsai CJ, Baxi S, Aghalar J, Eng J, et al. Randomized Phase II Trial of nivolumab with stereotactic body radiotherapy versus nivolumab alone in metastatic head and neck squamous cell carcinoma. J Clin Oncol. 2021;39(1):30–37. doi:10.1200/JCO.20.00290
   PubMed Web of Science ®Google Scholar
• Mao L, Zhou J-J, Xiao Y, Yang Q-C, Yang S-C, Wang S, et al. Immunogenic hypofractionated radiotherapy sensitising head and neck squamous cell carcinoma to anti-PD-L1 therapy in MDSC-dependent manner. Br J Cancer 2023;128(11):2126–2139. doi:10.1038/s41416-023-02230-0
   PubMed Web of Science ®Google Scholar
• Dok R, Glorieux M, Bamps M, Nuyts S. Effect of ATR inhibition in RT response of HPV-negative and HPV-positive head and neck cancers. Int J Mol Sci. 2021;22(4):1504. doi:10.3390/ijms22041504
   PubMed Web of Science ®Google Scholar
• Patin EC, Dillon MT, Nenclares P, Grove L, Soliman H, Leslie I, et al. Harnessing radiotherapy- – induced NK- – cell activity by combining DNA damage – response inhibition and immune checkpoint blockade. J Immunother Cancer. 2022;10(3):e004306. doi:10.1136/jitc-2021-004306
   PubMed Web of Science ®Google Scholar
• Saba NF, McDonald MW, McCook-Veal A, Stokes WA, Nasti T, Rudra S, et al. CA209-9KY: results of a Phase II study of intensity modulated radiotherapy (IMRT) re-irradiation and concurrent/adjuvant nivolumab (nivo) in patients with loco-regionally recurrent or second primary (RSPT) head and neck squamous cell carcinoma (HNSCC). J Clin Oncol. 2022;40(Suppl. 16):6029.
   Web of Science ®Google Scholar
• Pollack BP, Sapkota B, Cartee TV. Epidermal growth factor receptor inhibition augments the expression of MHC class I and II genes. Clin Cancer Res. 2011;17(13):4400–4413. doi:10.1158/1078-0432.CCR-10-3283
   PubMed Web of Science ®Google Scholar
• Chowell D, Morris LGT, Grigg CM, Weber JK, Samstein RM, Makarov V, et al. Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy. Science. 2018;359(6375):582–587. doi:10.1126/science.aao4572
   PubMed Web of Science ®Google Scholar
• Sacco AG, Chen R, Worden FP, Wong DJL, Adkins D, Swiecicki P, et al. Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, Phase II trial. Lancet Oncol. 2021;22(6):883–892. doi:10.1016/S1470-2045(21)00136-4
   PubMed Web of Science ®Google Scholar
• Gulati S, Crist M, Riaz MK, Takiar V, Lehn M, Monroe I, et al. Durvalumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell Carcinoma: an open-label, nonrandomized, Phase II clinical trial. Clin Cancer Res. 2023;29(10):1906–1915. doi:10.1158/1078-0432.CCR-22-3886
   PubMed Web of Science ®Google Scholar
• Chung CH, Bonomi M, Steuer CE, Li J, Bhateja P, Johnson M, et al. Concurrent cetuximab and nivolumab as a second-line or beyond treatment of patients with recurrent and/or metastatic head and neck squamous cell carcinoma: results of Phase I/II study. Cancers (Basel). 2021;13(5):1180. doi:10.3390/cancers13051180
   PubMed Web of Science ®Google Scholar
• Zhang S, Zheng M, Nie D, Xu L, Tian H, Wang M, et al. Efficacy of cetuximab plus PD-1 inhibitor differs by HPV status in head and neck squamous cell carcinoma: a systematic review and meta-analysis. J Immunother Cancer. 2022;10(10):e005158. doi:10.1136/jitc-2022-005158
   PubMed Web of Science ®Google Scholar
• Hanna GJ, Kaczmar JM, Zandberg DP, Wong DJL, Yilmaz E, Sherman EJ, et al. Dose expansion results of the bifunctional EGFR/TGFβ inhibitor BCA101 with pembrolizumab in patients with recurrent, metastatic head and neck squamous cell carcinoma. J Clin Oncol. 2023;41(Suppl. 16):6005. doi:10.1200/JCO.2023.41.16_suppl.6005
   Web of Science ®Google Scholar
• Chai AWY, Yee PS, Cheong SC. Rational combinations of targeted therapy and immune checkpoint inhibitors in head and neck cancers. Front Oncol. 2022;12:837835. doi:10.3389/fonc.2022.837835
   PubMedGoogle Scholar
• Micaily I, Johnson J, Argiris A. An update on angiogenesis targeting in head and neck squamous cell carcinoma. Cancers Head Neck. 2020;5:5. doi:10.1186/s41199-020-00051-9
   PubMedGoogle Scholar
• Fasano M, Della Corte CM, Viscardi G, Di Liello R, Paragliola F, Sparano F, et al. Head and neck cancer: the role of anti-EGFR agents in the era of immunotherapy. Ther Adv Med Oncol. 2021;13:1758835920949418. doi:10.1177/1758835920949418
   Web of Science ®Google Scholar
• Kao H-F, Liao B-C, Huang Y-L, Huang H-C, Chen C-N, Chen T-C, et al. Afatinib and pembrolizumab for recurrent or metastatic head and neck squamous cell carcinoma (ALPHA Study): a Phase II study with biomarker analysis. Clin Cancer Res. 2022;28(8):1560–1571. doi:10.1158/1078-0432.CCR-21-3025
   PubMed Web of Science ®Google Scholar
• Siu LL, Burtness B, Cohen EEW, Harrington KJ, Licitra LF, Rischin D, et al. Phase III LEAP-010 study: first-line pembrolizumab with or without lenvatinib in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). J Clin Oncol. 2020;38(Suppl. 15):TPS6589. doi:10.1200/JCO.2020.38.15_suppl.TPS6589
   Google Scholar
• Harrington KJ, Kong A, Mach N, Chesney JA, Fernandez BC, Rischin D, et al. Talimogene laherparepvec and pembrolizumab in recurrent or metastatic squamous cell carcinoma of the head and neck (MASTERKEY-232): a multicenter, Phase 1b Study. Clin Cancer Res. 2020;26(19):5153–5161. doi:10.1158/1078-0432.CCR-20-1170
   PubMed Web of Science ®Google Scholar
• Xu Y, Zhu G, Maroun CA, Wu IXY, Huang D, Seiwert TY, et al. Programmed death-1/programmed death-ligand 1-Axis blockade in recurrent or metastatic head and neck squamous cell carcinoma stratified by human papillomavirus status: a systematic review and meta-analysis. Front Immunol. 2021;12:1. doi:10.3389/fimmu.2021.645170
   Web of Science ®Google Scholar
• Julian R, Savani M, Bauman JE. Immunotherapy approaches in HPV-associated head and neck cancer. Cancers (Basel). 2021;13(23):5889. doi:10.3390/cancers13235889
   PubMed Web of Science ®Google Scholar
• Zuur L, Vos JL, Elbers JB, Krijgsman O, Qiao X, Van Der Leun A, et al. LBA40 neoadjuvant nivolumab and nivolumab plus ipilimumab induce (near-) complete responses in patients with head and neck squamous cell carcinoma: the IMCISION trial. Ann Oncol. 2020;31:S1169. doi:10.1016/j.annonc.2020.08.2270
   PubMed Web of Science ®Google Scholar
• Lee M, Samstein RM, Valero C, Chan TA, Morris LGT. Human vaccines & immunotherapeutics tumor mutational burden as a predictive biomarker for checkpoint inhibitor immunotherapy Hum Vaccin Immunother. 2020;16(1):112–115.
   PubMed Web of Science ®Google Scholar
• Tao Y, Biau J, Sun XS, Sire C, Martin L, Alfonsi M, et al. Pembrolizumab versus cetuximab concurrent with radiotherapy in patients with locally advanced squamous cell carcinoma of head and neck unfit for cisplatin (GORTEC 2015-01 PembroRad): a multicenter, randomized, Phase II trial. Ann Oncol. 2023;34(1):101–110. doi:10.1016/j.annonc.2022.10.006
   PubMed Web of Science ®Google Scholar
• Mell LK, Torres-Saavedra P, Wong S, Chang S, Kish JA, Minn AJ III, et al. Radiotherapy with durvalumab vs. cetuximab in patients with locoregionally advanced head and neck cancer and a contraindication to cisplatin: Phase II results of NRG-HN004. Int J Radiat Oncol Biol Phys. 2022;114(5):1058. doi:10.1016/j.ijrobp.2022.09.003
   Web of Science ®Google Scholar
• Klinghammer KF, Gauler TC, Stromberger C, Kofla G, de Wit M, Gollrad J, et al. DURTRERAD: a Phase II open-label study evaluating feasibility and efficacy of durvalumab (D) and durvalumab and tremelimumab (DT) in combination with radiotherapy (RT) in non-resectable locally advanced HPV-negative HNSCC-Results of the preplanned feasibi. J Clin Oncol. 2020;38(Suppl. 15):6574. doi:10.1200/JCO.2020.38.15_suppl.6574
   Web of Science ®Google Scholar
• Negative results from GORTEC-REACH study. https://dailyreporter.esmo.org/esmo-congress-2021/no-title/gortec-reach-study-results-fail-to-change-the-current-standard-of-care-for-locally-advanced-scchn
   Google Scholar
• Lee NY, Ferris RL, Psyrri A, Haddad RI, Tahara M, Bourhis J, et al. Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, Phase III trial. Lancet Oncol. 2021;22(4):450–462. doi:10.1016/S1470-2045(20)30737-3
   PubMed Web of Science ®Google Scholar
• Machiels J-P, Tao Y, Burtness B, Tahara M, Rischin D, Alves GV, et al. LBA5 primary results of the Phase III KEYNOTE-412 study: pembrolizumab (pembro) with chemoradiation therapy (CRT) vs placebo plus CRT for locally advanced (LA) head and neck squamous cell carcinoma (HNSCC). Ann Oncol. 2022;33:S1399. doi:10.1016/j.annonc.2022.08.029
   Google Scholar
• Pignon JP, le Maître A, Maillard E, Bourhis J. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol. 2009;92(1):4–14. doi:10.1016/j.radonc.2009.04.014
   PubMed Web of Science ®Google Scholar
• Clump DA, Zandberg DP, Skinner HD, Ohr J, Fenton MJ, Normolle DP, et al. A randomized Phase II study evaluating concurrent or sequential fixed-dose immune therapy in combination with cisplatin and intensity-modulated radiotherapy in intermediate- or high-risk, previously untreated, locally advanced head and neck cancer (LA SCC. J Clin Oncol. 2022;40(Suppl. 16):6007.
   Web of Science ®Google Scholar
• Mandal R, Şenbabaoğlu Y, Desrichard A, Havel JJ, Dalin MG, Riaz N, et al. The head and neck cancer immune landscape and its immunotherapeutic implications. JCI Insight. 2016;1(17):e89829. doi:10.1172/jci.insight.89829
   PubMed Web of Science ®Google Scholar
• Hecht M, Eckstein M, Rutzner S, von der Grün J, Illmer T, Klautke G, et al. Primary results of the Phase II CheckRad-CD8 trial: first-line treatment of locally advanced head and neck squamous cell carcinoma (HNSCC) with double checkpoint blockade and radiotherapy dependent on intratumoral CD8+ T-cell infiltration. J Clin Oncol. 2021;39(Suppl. 15):6007. doi:10.1200/JCO.2021.39.15_suppl.6007
   Web of Science ®Google Scholar
• Wennerberg E, Vanpouille-Box C, Bornstein S, Yamazaki T, Demaria S, Galluzzi L. Immune recognition of irradiated cancer cells. Immunol Rev. 2017;280(1):220–230. doi:10.1111/imr.12568
   PubMed Web of Science ®Google Scholar
• Barsoumian HB, Hsu J, Nanez S, Hu Y, Hsu EY, Riad TS, et al. The RadScopal Technique as an immune adjuvant to treat cancer. Immuno. 2023;3:74–85. doi:10.3390/immuno3010006
   Google Scholar
• Mavragani IV, Nikitaki Z, Souli MP, Aziz A, Nowsheen S, Aziz K, et al. Complex DNA damage: a route to radiation-induced genomic instability and carcinogenesis. Cancers (Basel). 2017;9(7):91. doi:10.3390/cancers9070091
   PubMed Web of Science ®Google Scholar
• Ermolaeva M, Schumacher B. The innate immune system as mediator of systemic DNA damage responses. Commun Integr Biol. 2013;6(6):e26926. doi:10.4161/cib.26926
   PubMedGoogle Scholar
• Punnanitinont A, Kannisto ED, Matsuzaki J, Odunsi K, Yendamuri S, Singh AK, et al. Sublethal radiation affects antigen processing and presentation genes to enhance immunogenicity of cancer cells. Int J Mol Sci. 2020;21(7):2573. doi:10.3390/ijms21072573
   PubMed Web of Science ®Google Scholar
• Saddawi-Konefka R, O'Farrell A, Faraji F, Clubb L, Allevato MM, Jensen SM, et al. Lymphatic-preserving treatment sequencing with immune checkpoint inhibition unleashes cDC1-dependent antitumor immunity in HNSCC. Nat Commun. 2022;13(1):4298. doi:10.1038/s41467-022-31941-w
   PubMedGoogle Scholar
• Uppaluri R, Campbell KM, Egloff AM, Zolkind P, Skidmore ZL, Nussenbaum B, et al. Neoadjuvant and adjuvant pembrolizumab in resectable locally advanced, human papillomavirus-unrelated head and neck cancer: a multicenter, Phase II trial. Clin Cancer Res. 2020;26(19):5140–5152. doi:10.1158/1078-0432.CCR-20-1695
   PubMed Web of Science ®Google Scholar
• Uppaluri R, Lee NY, Westra W, Cohen EEW, Haddad RI, Temam S, et al. KEYNOTE-689: Phase III study of adjuvant and neoadjuvant pembrolizumab combined with standard of care (SOC) in patients with resectable, locally advanced head and neck squamous cell carcinoma. J Clin Oncol. 2019;37(Suppl. 15):TPS6090–TPS6090. doi:10.1200/JCO.2019.37.15_suppl.TPS6090
   Web of Science ®Google Scholar
• Wise-Draper TM, Old MO, Worden FP, O'Brien PE, Cohen EEW, Dunlap N, et al. Phase II multi-site investigation of neoadjuvant pembrolizumab and adjuvant concurrent radiation and pembrolizumab with or without cisplatin in resected head and neck squamous cell carcinoma. J Clin Oncol. 2018;36(Suppl. 15):6017. doi:10.1200/JCO.2018.36.15_suppl.6017
   Web of Science ®Google Scholar
• Ferris RL, Spanos WC, Leidner R, Gonçalves A, Martens UM, Kyi C, et al. Neoadjuvant nivolumab for patients with resectable HPV-positive and HPV-negative squamous cell carcinomas of the head and neck in the CheckMate 358 trial. J Immunother Cancer. 2021;9:2568. doi:10.1136/jitc-2021-002568
   PubMed Web of Science ®Google Scholar
• Amin N, Maroun CA, El Asmar M, Alkhatib HH, Guller M, Herberg ME, et al. Neoadjuvant immunotherapy prior to surgery for mucosal head and neck squamous cell carcinoma: systematic review. Head Neck. 2022;44(2):562–571. doi:10.1002/hed.26935
   PubMed Web of Science ®Google Scholar
• Leidner R, Crittenden M, Young K, Xiao H, Wu Y, Couey MA, et al. Neoadjuvant immunoradiotherapy results in high rate of complete pathological response and clinical to pathological downstaging in locally advanced head and neck squamous cell carcinoma. J Immunother Cancer. 2021;9(5):e002485.
   PubMed Web of Science ®Google Scholar
• Weber JS, Carlino MS, Khattak A, Meniawy T, Ansstas G, Taylor MH, et al. Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, Phase IIb study. Lancet. 2024;403(10427):632–644. doi:10.1016/S0140-6736(23)02268-7
   PubMed Web of Science ®Google Scholar
• Crittenden MR, Zebertavage L, Kramer G, Bambina S, Friedman D, Troesch V, et al. Tumor cure by radiation therapy and checkpoint inhibitors depends on pre-existing immunity. Sci Rep. 2018;8(1):7012. doi:10.1038/s41598-018-25482-w
   PubMedGoogle Scholar
• Rasmussen JH, Lelkaitis G, Håkansson K, Vogelius IR, Johannesen HH, Fischer BM, et al. Intratumor heterogeneity of PD-L1 expression in head and neck squamous cell carcinoma. Br J Cancer 2019;120(10):1003–1006. doi:10.1038/s41416-019-0449-y
   PubMed Web of Science ®Google Scholar
• Cohen E, Fayette J, Harrington KJ, Johnson ML, Kao H-F, Lee S-H, et al. 927TiP SKYSCRAPER-09: a Phase II, randomised, double-blinded study of atezolizumab (Atezo) + tiragolumab (Tira) and atezo + placebo as first-line (1L) therapy for recurrent/metastatic (R/M) PD-L1+ squamous cell carcinoma of the head and neck (SCCHN). Ann Oncol. 2021;32:S814–S815. doi:10.1016/j.annonc.2021.08.1337
   PubMed Web of Science ®Google Scholar
• Li Y, Bi J, Pi G, He H, Li Y, Han G. Exploration of prognostic biomarkers in head and neck squamous cell carcinoma microenvironment from TCGA database. Ann Transl Med. 2023;11(4):163. doi:10.21037/atm-22-6481
   PubMedGoogle Scholar
• Lin AJ, Gang M, Rao YJ, Campian J, Daly M, Gay H, et al. Association of posttreatment lymphopenia and elevated neutrophil-to-lymphocyte ratio with poor clinical outcomes in patients with human papillomavirus-negative oropharyngeal cancers. JAMA Otolaryngol Head Neck Surg. 2019;145(5):413–421. doi:10.1001/jamaoto.2019.0034
   PubMed Web of Science ®Google Scholar
• Buchwald ZS, Nasti TH, Lee J, Eberhardt CS, Wieland A, Im SJ, et al. Tumor-draining lymph node is important for a robust abscopal effect stimulated by radiotherapy. J Immunother Cancer. 2020;8(2):e000867. doi:10.1136/jitc-2020-000867
   PubMed Web of Science ®Google Scholar
• Tran L, Allen CT, Xiao R, Moore E, Davis R, Park S-J, et al. Cisplatin alters antitumor immunity and synergizes with PD-1/PD-L1 inhibition in head and neck squamous cell carcinoma. Cancer Immunol Res. 2017;5(12):1141–1151. doi:10.1158/2326-6066.CIR-17-0235
   PubMed Web of Science ®Google Scholar
• Wang H, Mustafa A, Liu S, Liu J, Lv D, Yang H, et al. Immune checkpoint inhibitor toxicity in head and neck cancer: from identification to management. Front Pharmacol. 2019;10:1254. doi:10.3389/fphar.2019.01254
   PubMed Web of Science ®Google Scholar
• Wang Y, Springer S, Mulvey CL, Silliman N, Schaefer J, Sausen M, et al. Detection of somatic mutations and HPV in the saliva and plasma of patients with head and neck squamous cell carcinomas. Sci Transl Med. 2015;7(293):293ra104. doi:10.1126/scitranslmed.aaa8507
   PubMed Web of Science ®Google Scholar
• Pickering CR, Zhou JH, Lee JJ, Drummond JA, Peng SA, Saade RE, et al. Mutational landscape of aggressive cutaneous squamous cell carcinoma. Clin Cancer Res. 2014;20(24):6582–6592. doi:10.1158/1078-0432.CCR-14-1768
   PubMed Web of Science ®Google Scholar
• Dongre HN, Haave H, Fromreide S, Erland FA, Moe SEE, Dhayalan SM, et al. Targeted next-generation sequencing of cancer-related genes in a Norwegian patient cohort with head and neck squamous cell carcinoma reveals novel actionable mutations and correlations with pathological parameters. Front Oncol. 2021;11:734134. doi:10.3389/fonc.2021.734134
   PubMed Web of Science ®Google Scholar
• Bates JE, De Leo AN, Morris CG, Amdur RJ, Dagan R. Oligometastatic squamous cell carcinoma of the head and neck treated with stereotactic body ablative radiotherapy: single-institution outcomes. Head Neck. 2019;41(7):2309–2314. doi:10.1002/hed.25695
   PubMed Web of Science ®Google Scholar
• Franzese C, Badalamenti M, Teriaca A, De Virgilio A, Mercante G, Cavina R, et al. Metastasis-directed stereotactic body radiation therapy in the management of oligometastatic head and neck cancer. J Cancer Res Clin Oncol. 2021;147(5):1307–1313. doi:10.1007/s00432-021-03518-5
   PubMed Web of Science ®Google Scholar
• Husebye ES, Castinetti F, Criseno S, et al. Endocrine-related adverse conditions in patients receiving immune checkpoint inhibition: an ESE clinical practice guideline. Eur J Endocrinol.. 2022;187(6):G1–G21Lpage. doi:10.1530/EJE-22-0689
   PubMed Web of Science ®Google Scholar